Supernus Pharmaceuticals (SUPN) Revenue (2011 - 2025)

Supernus Pharmaceuticals (SUPN) has 15 years of Revenue data on file, last reported at $211.6 million in Q4 2025.

• Revenue for Q4 2025 came in at $211.6 million, up 21.48% year-over-year; the trailing twelve-month figure through Dec 2025 was $719.0 million (up 8.63% YoY), and the FY2025 annual result was $719.0 million, up 8.63% from the prior year.
• Revenue grew to $211.6 million in Q4 2025 per SUPN's latest filing, from $192.1 million in the prior quarter.
• Over five years, Revenue peaked at $211.6 million in Q4 2025 and troughed at $130.9 million in Q1 2021.
• A 5-year average of $161.8 million and a median of $161.7 million in 2021 frame the typical range for Revenue.
• The sharpest annual moves came in 2021 and 2023: Revenue soared 37.86% in 2021, then declined 20.28% in 2023.
• A 5-year view of Revenue shows it stood at $159.0 million in 2021, then grew by 5.2% to $167.3 million in 2022, then declined by 1.8% to $164.3 million in 2023, then gained by 5.99% to $174.2 million in 2024, then rose by 21.48% to $211.6 million in 2025.
• Business Quant data shows SUPN's Revenue at $211.6 million in Q4 2025, $192.1 million in Q3 2025, and $165.5 million in Q2 2025.